{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-09",
  
  "substances": [
    {
      "id": "psilocybin_001",
      "name": "Psilocybin",
      "aliases": ["Magic Mushrooms", "Shrooms"],
      "classification": {
        "primary": "classical_serotonergic_psychedelic",
        "secondary": ["tryptamine"],
        "mechanism": "5-HT2A_agonist",
        "receptorAffinity": {
          "5HT2A": "high",
          "5HT1A": "moderate",
          "5HT2C": "moderate"
        }
      },
      "metabolites": [
        {
          "name": "psilocin",
          "active": true,
          "conversionSite": "stomach",
          "conversionSpeed": "rapid",
          "halfLife": {"value": 163, "unit": "minutes"}
        }
      ],
      "prevalenceData": {
        "lifetimeUse": [
          {
            "value": 8.7,
            "unit": "percent",
            "population": "US adults 12+",
            "totalNumber": 22900000,
            "year": 2016,
            "citations": ["carbonaro_2016"]
          },
          {
            "value": 11.7,
            "unit": "percent",
            "population": "Canadian adults",
            "context": "lifetime use",
            "citations": ["lake_2023"]
          }
        ],
        "emergencyRoomVisits": {
          "rate": 1,
          "unit": "percent",
          "year": 2020,
          "context": "Of all users seeking emergency care",
          "citations": ["canady_2023"]
        },
        "initiationPatterns": {
          "percentStartingWithPsilocybin": 52,
          "timeframe": "2004-2005",
          "context": "Among those initiating hallucinogen use",
          "citations": ["carbonaro_2016"]
        }
      },
      "dosing": {
        "microdose": {
          "dried_mushrooms": {"min": 0.1, "max": 0.5, "unit": "grams"},
          "synthetic": {"min": 0.8, "max": 5, "unit": "mg"},
          "notes": "1/10th to 1/20th of recreational dose",
          "commonSchedule": "1 day on, 2 days off"
        },
        "threshold": {"value": 2, "unit": "mg"},
        "light": {"min": 3, "max": 6, "unit": "mg"},
        "common": {"min": 6, "max": 15, "unit": "mg"},
        "strong": {"min": 15, "max": 30, "unit": "mg"},
        "heavy": {"min": 30, "unit": "mg"},
        "therapeutic": {
          "typical": {"value": 25, "unit": "mg"},
          "range": {"min": 1.75, "max": 30, "unit": "mg"},
          "median": {"value": 21, "unit": "mg", "context": "for 70kg participant"}
        },
        "recreational": {"min": 1, "max": 5, "unit": "grams_dried"},
        "weightDependence": false,
        "notes": "Body weight does not significantly influence effects"
      },
      "pharmacokinetics": {
        "absorption": {
          "route": "oral",
          "fastingEffect": "May enhance experience",
          "conversionSite": "predominantly stomach"
        },
        "onset": {"min": 20, "max": 40, "unit": "minutes"},
        "peak": {"min": 60, "max": 90, "unit": "minutes"},
        "duration": {"min": 3, "max": 6, "unit": "hours"},
        "metabolism": "Rapidly converted to psilocin in stomach",
        "elimination": "renal"
      },
      "subjectiveEffectTimeline": {
        "acute": {
          "timeframe": "0-180 minutes",
          "predominantEffects": [
            "emotional_excitement",
            "heightened_mood",
            "increased_concentration",
            "depersonalization",
            "derealization",
            "altered_time_perception"
          ]
        },
        "subacute": {
          "timeframe": "260-400 minutes",
          "predominantEffects": [
            "dreaminess",
            "inactivation",
            "introversion",
            "intensified_derealization",
            "intensified_depersonalization"
          ]
        },
        "longTerm": {
          "timeframe": "8-16 months post",
          "retrospectiveEvaluation": {
            "highlyEnriching": ">60%",
            "moderatelyEnriching": ">90%",
            "note": "Consistent even among those with acute distress"
          }
        }
      },
      "toleranceDevelopment": {
        "rate": "rapid",
        "crossTolerance": ["LSD", "mescaline"],
        "duration": "3-7 days for reset"
      },
      "addictionPotential": "minimal",
      "physiologicalDependence": "none reported",
      "psychologicalDependence": "rare"
    }
  ],

  "setFactors": [
    {
      "id": "set_expectations_001",
      "name": "Expectations and Intentions",
      "category": "cognitive",
      "description": "Individual's mindset, goals, and expectations entering experience",
      "components": [
        {
          "name": "Intentions",
          "importance": "high",
          "effect": "Clear intentions associated with better outcomes",
          "riskOfAbsence": "Confusion, disorientation, difficulty integrating",
          "citations": ["campo_2024", "haijen_2018"]
        },
        {
          "name": "Expectations",
          "importance": "high",
          "effect": "Unrealistic expectations can lead to disappointment or distress",
          "mediatingFactors": ["media_portrayal", "peer_reports", "preparation_quality"],
          "citations": ["romeo_2024", "palitsky_nd"]
        }
      ],
      "assessmentTools": ["Dysfunctional Attitude Scale"],
      "modifiability": "high",
      "interventions": ["preparation_sessions", "psychoeducation", "intention_setting_exercises"]
    },
    {
      "id": "set_personality_001",
      "name": "Personality Traits",
      "category": "trait",
      "traits": [
        {
          "trait": "Neuroticism",
          "effect": "negative",
          "strength": "strong_predictor",
          "specificRisks": ["anxiety", "panic", "paranoia"],
          "citations": ["barrett_2017", "breeksema_2022", "gorman_2021"]
        },
        {
          "trait": "Openness to Experience",
          "effect": "positive",
          "strength": "moderate_predictor",
          "specificBenefits": ["mystical_experiences", "better_navigation_of_novel_states"],
          "citations": ["breeksema_2022", "aday_2021"]
        },
        {
          "trait": "Suggestibility",
          "effect": "risk_factor",
          "specificRisks": ["susceptible_to_influence", "belief_manipulation"],
          "citations": ["neitzke-spruill_2024", "halpern_2018"]
        }
      ],
      "assessmentTools": ["Big Five Inventory", "NEO-PI-R"],
      "modifiability": "low"
    },
    {
      "id": "set_surrender_001",
      "name": "Psychological Flexibility and Surrender",
      "category": "state",
      "description": "Ability to accept and surrender to experience",
      "effect": "Strong predictor of positive experience",
      "oppositeState": "Resistance, preoccupation, rumination",
      "oppositeEffect": "Associated with difficult experiences and poor outcomes",
      "citations": ["fogg_2021"],
      "interventions": ["mindfulness_training", "acceptance_commitment_therapy_concepts"],
      "modifiability": "moderate_to_high"
    }
  ],

  "riskFactors": [
    {
      "id": "rf_cardiovascular_001",
      "name": "Pre-existing cardiovascular conditions",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "description": "Heart conditions, hypertension, arrhythmias",
      "severity": "high",
      "prevalence": {
        "generalPopulation": "Variable by age and condition",
        "exclusionFromTrials": "common"
      },
      "substanceInteractions": [
        {
          "substanceId": "psilocybin_001",
          "mechanism": "Increases blood pressure, heart rate, and body temperature",
          "riskLevel": "moderate_to_high",
          "specificConditions": [
            {
              "condition": "uncontrolled_hypertension",
              "contraindicationType": "absolute",
              "severity": "critical"
            },
            {
              "condition": "arrhythmias",
              "contraindicationType": "absolute",
              "severity": "critical"
            },
            {
              "condition": "recent_MI",
              "contraindicationType": "absolute",
              "timeframe": "Within 6 months",
              "severity": "critical"
            },
            {
              "condition": "coronary_artery_disease",
              "contraindicationType": "relative",
              "requiresMonitoring": true,
              "severity": "high"
            }
          ],
          "physiologicalEffects": {
            "bloodPressure": {
              "increase": "moderate",
              "systolic": ">160 mmHg reported",
              "diastolic": ">100 mmHg reported",
              "context": "Especially in older patients"
            },
            "heartRate": {
              "increase": "moderate",
              "tachycardia": "Heart rate >100 bpm in 7% of administrations"
            },
            "bodyTemperature": {
              "increase": "mild_to_moderate"
            }
          },
          "citations": ["anderson_2020", "wsol_2023", "marazziti_2024", "bender_2022"],
          "evidenceQuality": "moderate"
        },
        {
          "substanceId": "mdma_001",
          "mechanism": "Transient increases in BP and HR, sympathomimetic effects",
          "riskLevel": "high",
          "specificRisks": ["myocardial_infarction", "hypertensive_crisis", "arrhythmia"],
          "citations": ["vollenweider_1998", "makunts_2023"],
          "evidenceQuality": "strong",
          "additionalConsiderations": "Exacerbated by hot environments and physical exertion"
        }
      ],
      "prevalenceInTrials": "Often excluded",
      "clinicalSignificance": "May increase risk of acute cardiovascular events",
      "monitoringRecommendations": [
        "Baseline ECG",
        "Continuous vital sign monitoring during session",
        "Medical supervision required"
      ]
    },
    {
      "id": "rf_trauma_history_001",
      "name": "Unprocessed Trauma History",
      "category": "psychiatric",
      "subcategory": "trauma",
      "description": "History of traumatic experiences, especially if unresolved",
      "severity": "moderate_to_high",
      "substanceInteractions": [
        {
          "substanceId": "psilocybin_001",
          "mechanism": "Trauma reactivation during psychedelic state",
          "riskLevel": "moderate",
          "specificRisks": [
            "trauma_reexperiencing",
            "emotional_distress",
            "destabilization"
          ],
          "prevalenceOfReexperiencing": {
            "ptsdDiagnosis": 37.5,
            "unit": "percent",
            "context": "In ceremonial ayahuasca study",
            "citation": "weiss_2023"
          },
          "nuancedConsiderations": {
            "therapeuticPotential": "May be beneficial with proper support",
            "requiredSupport": [
              "Trauma-informed therapy",
              "Specialized integration support",
              "Safety planning"
            ]
          },
          "genderConsiderations": {
            "sexualAssaultReexperiencing": {
              "prevalence": "high",
              "population": "women",
              "context": "ayahuasca ceremonies",
              "citation": "weiss_2023"
            }
          },
          "citations": ["bremler_2023", "gorman_2021", "weiss_2023", "scala_2024"],
          "evidenceQuality": "moderate"
        }
      ],
      "contraindicationType": "relative",
      "requiresSpecializedSupport": true,
      "preparationConsiderations": [
        "Trauma processing work prior to session",
        "Safety plan development",
        "Grounding techniques training",
        "Therapeutic support availability"
      ]
    },
    {
      "id": "rf_polydrug_use_001",
      "name": "Concurrent Polydrug Use",
      "category": "behavioral",
      "subcategory": "substance_use",
      "description": "Use of multiple substances simultaneously or in close temporal proximity",
      "severity": "high",
      "prevalence": {
        "inDeaths": {
          "value": 82,
          "unit": "percent",
          "context": "Most common theme in psychedelic-related deaths",
          "citation": "kopra_2025"
        }
      },
      "substanceInteractions": [
        {
          "substanceId": "*",
          "mechanism": "Unpredictable interactions, increased physiological burden",
          "riskLevel": "high",
          "specificCombinations": [
            {
              "substances": ["psilocybin", "alcohol"],
              "effect": "Increased adverse effects"
            },
            {
              "substances": ["psilocybin", "cannabis"],
              "effect": "Variable - may reduce or exacerbate difficulty",
              "prevalence": "common combination",
              "citation": "carbonaro_2016"
            },
            {
              "substances": ["any_psychedelic", "SSRIs"],
              "effect": "Serotonin syndrome risk",
              "severity": "critical",
              "mechanism": "Excessive serotonin accumulation"
            },
            {
              "substances": ["any_psychedelic", "MAOIs"],
              "effect": "Severe serotonin syndrome, potentially fatal",
              "severity": "critical",
              "contraindicationType": "absolute"
            }
          ],
          "citations": ["kopra_2025", "breeksema_2022", "malcolm_2022"]
        }
      ],
      "harmReductionStrategies": [
        "Substance testing",
        "Avoiding combinations",
        "Education about dangerous interactions",
        "Medication review before sessions"
      ]
    },
    {
      "id": "rf_age_youth_001",
      "name": "Adolescence and Young Adulthood",
      "category": "demographic",
      "subcategory": "age",
      "ageRange": {"min": 13, "max": 25},
      "description": "Younger age associated with increased vulnerability",
      "severity": "moderate_to_high",
      "substanceInteractions": [
        {
          "substanceId": "*",
          "mechanism": "Developing brain more susceptible to disruption",
          "riskLevel": "elevated",
          "specificRisks": [
            "negative_psychological_effects",
            "higher_emergency_treatment_rates",
            "potential_developmental_disruption"
          ],
          "prevalenceData": {
            "negativeEffects": {
              "value": 53,
              "unit": "percent",
              "context": "Of those with negative effects were under 25",
              "citation": "bremler_2023"
            },
            "poisonControlCases": {
              "ageGroup": "13-19",
              "substance": "LSD and psilocybin",
              "prevalence": "majority",
              "citation": "malcolm_2022"
            }
          },
          "mechanisticFactors": [
            "Neurotransmitter system susceptibility",
            "Ongoing brain development",
            "Lower risk aversion",
            "Higher impulsivity",
            "Difficulty with emotional regulation"
          ],
          "citations": ["marazziti_2024", "breeksema_2022", "bremler_2023", "malcolm_2022"]
        }
      ],
      "recommendations": [
        "Extra caution",
        "Careful screening",
        "Age-appropriate education",
        "Parental/guardian involvement where appropriate"
      ]
    },
    {
      "id": "rf_genetic_metabolism_001",
      "name": "Genetic Metabolic Variations",
      "category": "physiological",
      "subcategory": "pharmacogenetics",
      "description": "Individual genetic variations in drug metabolism",
      "severity": "moderate",
      "specificGeneticFactors": [
        {
          "gene": "CYP2D6",
          "relevantSubstances": ["MDMA", "ibogaine"],
          "variants": [
            {
              "type": "poor_metabolizer",
              "frequency": "5-10% of population",
              "effect": "Higher plasma concentrations, increased risk of toxicity",
              "citations": ["sarparast_2022", "papaseit_2018"]
            },
            {
              "type": "ultra_rapid_metabolizer",
              "frequency": "1-2% of population",
              "effect": "Lower plasma concentrations, potentially reduced effects"
            }
          ]
        },
        {
          "gene": "CYP1A2",
          "relevantSubstances": ["MDMA"],
          "effect": "Influences metabolism rate"
        },
        {
          "gene": "CYP2B6",
          "relevantSubstances": ["MDMA"],
          "effect": "Influences metabolism rate"
        },
        {
          "gene": "CYP2C19",
          "relevantSubstances": ["MDMA"],
          "effect": "Influences metabolism rate"
        }
      ],
      "clinicalImplications": "May require dose adjustment or additional monitoring",
      "futureDirections": "Pharmacogenetic screening may become standard practice"
    },
    {
      "id": "rf_gender_sex_001",
      "name": "Sex and Gender Differences",
      "category": "demographic",
      "subcategory": "sex_gender",
      "description": "Biological sex and gender-related risk factors",
      "substanceInteractions": [
        {
          "substanceId": "mdma_001",
          "sexDifferences": {
            "female": {
              "plasmaConcentrations": "higher",
              "subjectiveEffects": "more intense",
              "specificEffects": [
                "More perceptual changes",
                "More anxiety",
                "More depression",
                "More frequent acute adverse effects",
                "More subacute adverse effects"
              ],
              "hyponatremiaRisk": {
                "level": "elevated",
                "mechanism": "Lower BMI associated with higher risk",
                "prevalence": "Lower BMI individuals at higher risk"
              },
              "comedownEffects": "More adverse mood effects than men",
              "citations": ["papaseit_2018", "atila_2024", "parrott_2014"]
            }
          },
          "riskLevel": "moderate",
          "evidenceQuality": "moderate"
        },
        {
          "substanceId": "ayahuasca_001",
          "genderConsiderations": {
            "female": {
              "sexualAssaultReexperiencing": {
                "prevalence": "high",
                "context": "During ceremonies",
                "citation": "weiss_2023"
              },
              "physicalAdverseEffects": {
                "prevalence": "higher probability",
                "citation": "bouso_2022"
              }
            }
          }
        }
      ],
      "recommendations": [
        "Sex-stratified dosing considerations for MDMA",
        "Additional monitoring for women using MDMA",
        "Trauma-informed approaches for women with assault history"
      ]
    }
  ],

  "medicalConditions": [
    {
      "id": "cond_bipolar_001",
      "name": "Bipolar Disorder",
      "category": "psychiatric",
      "icd10": "F31",
      "subtypes": [
        {
          "type": "Bipolar I",
          "description": "With manic episodes",
          "riskLevel": "high"
        },
        {
          "type": "Bipolar II",
          "description": "With hypomanic episodes",
          "riskLevel": "moderate",
          "emergingEvidence": "Recent research shows safety in controlled settings"
        }
      ],
      "substanceRisks": [
        {
          "substanceId": "psilocybin_001",
          "contraindicationType": "relative",
          "activeState": "absolute",
          "stableState": "relative",
          "specificRisks": [
            {
              "risk": "manic_episode_induction",
              "prevalence": "Unknown but documented",
              "severity": "high"
            }
          ],
          "emergingEvidence": {
            "study": "Bipolar II treatment-resistant depression with psilocybin",
            "finding": "No increases in mania or hypomania",
            "context": "Controlled therapeutic setting",
            "implication": "May be safe for this specific population with proper protocols",
            "citation": "honk_2024"
          },
          "requiredPrecautions": [
            "Careful screening",
            "Comprehensive preparation",
            "Close monitoring",
            "Integration support",
            "Medication review"
          ],
          "citations": ["honk_2024", "rosenblat_2023"],
          "screening": "Essential - requires careful screening, preparation, and support",
          "evidenceQuality": "emerging"
        },
        {
          "substanceId": "lsd_001",
          "contraindicationType": "absolute_if_active",
          "relativeIfStable": true,
          "citations": ["honk_2024", "marrocu_nd"]
        },
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "relative",
          "activeState": "absolute",
          "historicalRisk": {
            "manicEpisodes": "documented",
            "severity": "high"
          }
        }
      ],
      "familyHistory": {
        "relevant": true,
        "contraindicationType": "relative",
        "riskMultiplier": "elevated"
      },
      "prevalence": {
        "globalLifetime": "2.4%",
        "note": "Varies by diagnostic criteria and population"
      }
    },
    {
      "id": "cond_personality_disorders_001",
      "name": "Personality Disorders",
      "category": "psychiatric",
      "icd10": "F60-F69",
      "description": "Cluster of personality disorders including borderline, antisocial, etc.",
      "substanceRisks": [
        {
          "substanceId": "*",
          "contraindicationType": "relative",
          "riskLevel": "high",
          "specificRisks": {
            "negativeResponse": {
              "probability": 31,
              "unit": "percent",
              "relativeTo": "general_population"
            },
            "adversePsychologicalResponse": {
              "riskMultiplier": 4,
              "description": "Greater than four-fold elevated risk",
              "citation": "marrocu_nd"
            },
            "longTermNegativeResponse": {
              "associated": true,
              "severity": "moderate_to_high",
              "citation": "bremler_2023"
            }
          },
          "citations": ["marrocu_nd", "bremler_2023"],
          "evidenceQuality": "moderate",
          "requiredPrecautions": [
            "Thorough screening",
            "Enhanced preparation",
            "Increased therapeutic support",
            "Careful monitoring",
            "Extended integration"
          ]
        }
      ]
    }
  ],

  "adverseEvents": [
    {
      "id": "ae_anxiety_acute_001",
      "name": "Acute Anxiety",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Anxiety experienced during or shortly after psychedelic administration",
      "temporalPattern": {
        "onset": "During session",
        "duration": "Typically resolves with session",
        "persistence": "May last hours beyond peak effects in some cases"
      },
      "substanceOccurrence": [
        {
          "substanceId": "psilocybin_001",
          "prevalence": [
            {
              "value": 31,
              "unit": "percent",
              "context": "During session in clinical trial",
              "persistence": "Did not persist beyond treatment",
              "citation": "forstmann_2021"
            },
            {
              "value": 15.6,
              "unit": "percent",
              "context": "On day of session (combined analysis)",
              "citation": "freitas_2024"
            },
            {
              "rangeValue": {"min": 2, "max": 100},
              "unit": "percent",
              "context": "Wide variation across studies",
              "citation": "freitas_2024"
            }
          ],
          "management": {
            "primary": "reassurance",
            "effectiveness": "Usually sufficient",
            "escalation": "Benzodiazepines if reassurance insufficient"
          },
          "resolutionTime": "Usually resolves with session",
          "citations": ["freitas_2024", "scala_2024", "forstmann_2021"]
        },
        {
          "substanceId": "mdma_001",
          "prevalence": {
            "description": "Most common psychological adverse event",
            "context": "Acute phase"
          },
          "citations": ["breeksema_2022"]
        },
        {
          "substanceId": "lsd_001",
          "prevalence": [
            {
              "value": 64.1,
              "unit": "percent",
              "context": "First-time users experienced some level of fear",
              "severity": "Generally mild",
              "impact": "Did not discourage further use",
              "citation": "baxter_2024"
            },
            {
              "value": 69.6,
              "unit": "percent",
              "context": "Emergency medical treatment seekers",
              "coOccurrence": "Often with confusion (64.1%)",
              "citation": "kopra_2022"
            }
          ]
        },
        {
          "substanceId": "5meo_dmt_001",
          "prevalence": {
            "timing": "Particularly prior to and during onset (first 10-15 minutes)",
            "citations": ["ramaekers_2025", "rucker_2024"]
          }
        }
      ],
      "riskFactors": [
        "rf_anxiety_history_001",
        "rf_unprepared_001",
        "rf_unfamiliar_setting_001",
        "rf_high_dose_001",
        "rf_neuroticism_001"
      ],
      "associatedWithWorseningInLongTerm": {
        "prevalence": 87,
        "unit": "percent",
        "context": "Among those with negative psychological responses",
        "citation": "bremler_2023"
      },
      "clinicalSignificance": "Usually transient but can escalate without proper support",
      "interventions": [
        "verbal_reassurance",
        "breathing_exercises",
        "grounding_techniques",
        "environmental_adjustment",
        "benzodiazepines_if_severe"
      ]
    },
    {
      "id": "ae_hppd_001",
      "name": "Hallucinogen Persisting Perception Disorder (HPPD)",
      "category": "perceptual",
      "timeframe": "long_term",
      "severity": "variable",
      "description": "Persistent perceptual disturbances long after drug effects have worn off",
      "types": [
        {
          "type": "type_1",
          "description": "Transient, benign flashback",
          "duration": "short_term",
          "distress": "minimal",
          "functionalImpairment": "none_to_minimal"
        },
        {
          "type": "type_2",
          "description": "Chronic, potentially distressing",
          "duration": "long_term",
          "distress": "moderate_to_severe",
          "functionalImpairment": "variable"
        }
      ],
      "substanceOccurrence": [
        {
          "substanceId": "lsd_001",
          "prevalence": {
            "reported": [
              {
                "value": {"min": 10, "max": 15},
                "unit": "percent",
                "context": "Visual disturbances without further drug use",
                "citation": "halpern_2003"
              },
              {
                "value": 10,
                "unit": "percent",
                "context": "Long-term perceptual changes when asked directly",
                "significance": "73% did not consider changes significant",
                "citation": "carhart-harris_2010"
              }
            ],
            "wideRange": "15-77% across studies",
            "clinicallySignificant": "Small minority experience distress/impairment",
            "methodologicalConcerns": "Rates may be inflated"
          },
          "symptoms": [
            {
              "symptom": "visual_distortions",
              "examples": ["visual_snow", "intensified_colors", "trailing"]
            },
            {
              "symptom": "flashes",
              "frequency": "variable"
            },
            {
              "symptom": "geometric_patterns",
              "frequency": "variable"
            },
            {
              "symptom": "palinopsia",
              "description": "Persistence of visual images"
            },
            {
              "symptom": "afterimages",
              "description": "Prolonged afterimages"
            }
          ],
          "dissociativeSymptoms": [
            "depersonalization",
            "derealization"
          ],
          "citations": ["halpern_2003", "carhart-harris_2010", "ortiz_bernal_2022"],
          "evidenceQuality": "moderate"
        },
        {
          "substanceId": "psilocybin_001",
          "prevalence": {
            "questionnaire": 25,
            "interview": 40,
            "unit": "percent",
            "context": "Among users with negative effects",
            "clinicallySignificant": "Small minority",
            "citation": "bremler_2023"
          },
          "comparisonToLSD": "Less common than LSD",
          "citations": ["rosenblat_2023", "scala_2024"]
        },
        {
          "substanceId": "25i_nbome_001",
          "prevalence": {
            "regular_use": 67,
            "single_use": 20,
            "unit": "percent",
            "context": "Chronic or prolonged effects",
            "citation": "retrospective_analysis_nd"
          },
          "riskPattern": "Higher risk with regular use"
        }
      ],
      "riskFactors": [
        {
          "factor": "rf_frequent_use_001",
          "evidence": "strong"
        },
        {
          "factor": "rf_high_dose_001",
          "evidence": "moderate"
        },
        {
          "factor": "rf_polydrug_use_001",
          "evidence": "moderate",
          "specificCombinations": ["alcohol", "cannabis"]
        },
        {
          "factor": "rf_younger_age_001",
          "evidence": "emerging",
          "citation": "lacroix_2024"
        },
        {
          "factor": "rf_substance_misuse_history_001",
          "evidence": "moderate",
          "citation": "martinotti_2018"
        }
      ],
      "onsetPattern": {
        "singleUse": "possible",
        "chronicUse": "more_common",
        "timing": "Can occur immediately or develop gradually"
      },
      "clinicalTrialsData": {
        "contemporary": "No cases reported in contemporary clinical trials",
        "context": "Controlled settings with screening",
        "citation": "lacroix_2024"
      },
      "treatmentApproaches": [
        {
          "approach": "benzodiazepines",
          "evidence": "anecdotal"
        },
        {
          "approach": "lamotrigine",
          "evidence": "case_reports"
        },
        {
          "approach": "reassurance",
          "evidence": "clinical_experience"
        },
        {
          "approach": "cognitive_behavioral_therapy",
          "evidence": "limited"
        }
      ],
      "differentialDiagnosis": [
        "persistent_migraine_aura",
        "visual_snow_syndrome",
        "anxiety_disorder",
        "psychotic_disorder"
      ]
    },
    {
      "id": "ae_serotonin_syndrome_001",
      "name": "Serotonin Syndrome",
      "category": "physiological",
      "subcategory": "neurotoxicity",
      "timeframe": "acute",
      "severity": "severe_to_critical",
      "description": "Potentially life-threatening condition from excessive serotonin",
      "symptoms": {
        "autonomic": [
          "hyperthermia",
          "tachycardia",
          "hypertension",
          "diaphoresis",
          "mydriasis"
        ],
        "neuromuscular": [
          "muscle_rigidity",
          "tremor",
          "hyperreflexia",
          "clonus",
          "myoclonus"
        ],
        "cognitive": [
          "agitation",
          "confusion",
          "delirium"
        ],
        "severe": [
          "seizures",
          "rhabdomyolysis",
          "disseminated_intravascular_coagulation",
          "death"
        ]
      },
      "substanceOccurrence": [
        {
          "substanceId": "mdma_001",
          "prevalence": "Rare in clinical settings; more common with polydrug use",
          "mechanism": "Excessive serotonin release and reuptake inhibition",
          "riskFactors": [
            "Concurrent SSRI use",
            "Concurrent MAOI use",
            "High doses",
            "Polydrug use",
            "Poor metabolizers"
          ],
          "citations": ["malcolm_2022", "gomez-escolar_2024"]
        },
        {
          "substanceId": "5meo_dmt_001",
          "riskLevel": "critical",
          "triggeringCombinations": [
            {
              "combination": "5-MeO-DMT + MAOIs",
              "severity": "potentially_fatal",
              "evidence": "case_reports",
              "citations": ["malcolm_2022"]
            },
            {
              "combination": "5-MeO-DMT + harmala_alkaloids",
              "severity": "critical",
              "mechanism": "MAO inhibition increases 5-MeO-DMT exposure sixfold",
              "citations": ["malcolm_2022"]
            }
          ]
        }
      ],
      "onset": "Rapid (minutes to hours after exposure)",
      "duration": "Variable; requires medical management",
      "treatment": {
        "primary": "Discontinuation of serotonergic agents",
        "supportive": [
          "Benzodiazepines",
          "Cooling measures",
          "IV fluids",
          "Vital sign monitoring"
        ],
        "severe": [
          "ICU admission",
          "Serotonin antagonists (cyproheptadine)",
          "Intubation if needed"
        ]
      },
      "prevention": {
        "screening": "Medication review essential",
        "education": "Clear warnings about dangerous combinations",
        "avoidance": "Absolute contraindication for certain combinations"
      },
      "mortality": "Can be fatal without treatment"
    },
    {
      "id": "ae_hyponatremia_001",
      "name": "Hyponatremia",
      "category": "physiological",
      "subcategory": "electrolyte",
      "timeframe": "acute",
      "severity": "moderate_to_severe",
      "description": "Abnormally low sodium levels in blood",
      "clinicalDefinition": "Plasma sodium <135 mEq/L",
      "severeCutoff": "Plasma sodium <120 mEq/L",
      "substanceOccurrence": [
        {
          "substanceId": "mdma_001",
          "prevalence": {
            "clinical": [
              {
                "value": 37,
                "unit": "percent",
                "context": "Controlled study with unrestricted fluid intake",
                "citation": "atila_2024"
              },
              {
                "value": 31,
                "unit": "percent",
                "context": "With fluid restriction intervention",
                "citation": "atila_2024"
              }
            ],
            "emergency": {
              "range": "101-130 mEq/L at admission",
              "context": "Life-threatening cases",
              "presentation": "Single dose exposure"
            }
          },
          "mechanism": [
            "Inappropriate ADH secretion",
            "Excessive water intake",
            "Increased water retention",
            "Physical exertion with hypotonic fluid replacement"
          ],
          "riskFactors": [
            {
              "factor": "female_sex",
              "rationale": "Higher plasma MDMA concentrations"
            },
            {
              "factor": "low_BMI",
              "rationale": "Associated with higher risk",
              "citation": "atila_2024"
            },
            {
              "factor": "high_temperature_environment",
              "context": "Nightclubs, festivals"
            },
            {
              "factor": "overhydration_with_hypotonic_fluids",
              "mechanism": "Dilutional hyponatremia"
            },
            {
              "factor": "physical_exertion",
              "context": "Dancing, prolonged activity"
            }
          ],
          "symptoms": {
            "mild": ["nausea", "headache", "confusion"],
            "moderate": ["vomiting", "muscle_weakness"],
            "severe": ["seizures", "coma", "death"]
          },
          "prevention": [
            "Fluid restriction during session",
            "Education about appropriate hydration",
            "Avoid hypotonic fluids",
            "Monitor environment temperature"
          ],
          "treatment": [
            "Fluid restriction",
            "Hypertonic saline if severe",
            "Electrolyte monitoring",
            "Hospital admission if severe"
          ],
          "citations": ["atila_2024", "barnett_2021", "edwards_2023"],
          "evidenceQuality": "strong"
        }
      ]
    }
  ],

  "therapeuticAlliance": [
    {
      "id": "alliance_quality_001",
      "name": "Therapeutic Alliance Quality",
      "category": "relational",
      "description": "Quality of relationship between therapist/facilitator and participant",
      "importance": "critical",
      "impact": "Strong predictor of outcomes",
      "components": [
        {
          "component": "safety",
          "description": "Participant feels physically and emotionally safe"
        },
        {
          "component": "trust",
          "description": "Confidence in facilitator's competence and intentions"
        },
        {
          "component": "collaboration",
          "description": "Shared decision-making and goals"
        },
        {
          "component": "empathy",
          "description": "Facilitator's ability to understand participant's experience"
        }
      ],
      "positiveCharacteristics": [
        "open",
        "empathetic",
        "non-judgmental",
        "warm",
        "present",
        "culturally_sensitive"
      ],
      "negativeCharacteristics": [
        "rigid",
        "critical",
        "distant",
        "distracted",
        "imposing_beliefs",
        "boundary_violations"
      ],
      "amplificationFactors": {
        "description": "Psychedelics amplify transference and countertransference",
        "specificRisks": [
          "Idealization of therapist",
          "Projection onto therapist",
          "Dependency development",
          "Power imbalance exploitation"
        ],
        "citations": ["evans_holcomb_2025", "modlin_2023"]
      },
      "assessment": "Measured through validated alliance scales",
      "interventions": [
        "Multiple preparation sessions to build rapport",
        "Therapist training in alliance building",
        "Regular supervision",
        "Participant feedback mechanisms"
      ],
      "evidenceForImportance": [
        {
          "finding": "Strong alliance associated with better outcomes",
          "citation": "garcia-romeu_2018"
        },
        {
          "finding": "Weak alliance associated with poorer outcomes",
          "citation": "modlin_2023"
        },
        {
          "finding": "Rapport mediates emotional breakthrough and mystical experiences",
          "citation": "davis_nd"
        }
      ]
    }
  ],

  "boundaryViolations": [
    {
      "id": "boundary_sexual_001",
      "name": "Sexual Misconduct",
      "category": "ethical_violation",
      "severity": "critical",
      "description": "Sexual touching, contact, or exploitation during psychedelic therapy",
      "prevalenceData": [
        {
          "value": 8,
          "unit": "percent",
          "context": "Naturalistic users knowing someone victimized",
          "perpetrators": "Sitters, guides, or practitioners",
          "citation": "kruger_2024"
        },
        {
          "value": 46.3,
          "unit": "percent",
          "context": "Of sexual misconduct perpetrators were underground sitters/guides",
          "citation": "kruger_2024"
        },
        {
          "value": 7.9,
          "unit": "percent",
          "context": "Participants knowing someone who experienced sexual violations",
          "citation": "kruger_2024"
        }
      ],
      "riskFactors": [
        "Heightened suggestibility during psychedelic state",
        "Vulnerability and trust",
        "Power imbalances",
        "Lack of clear ethical guidelines",
        "Inadequate practitioner training",
        "Absence of oversight"
      ],
      "prevention": [
        "Clear ethical boundaries",
        "Training on power dynamics",
        "Same-gender therapist options",
        "Multiple therapists present",
        "Video recording (with consent)",
        "Reporting mechanisms",
        "Licensing and oversight"
      ],
      "citations": ["kruger_2024", "holoyda_2023", "barber_2023"],
      "legalConsiderations": [
        "Criminal prosecution possible",
        "Civil liability",
        "Professional license revocation"
      ]
    },
    {
      "id": "boundary_financial_001",
      "name": "Financial Exploitation",
      "category": "ethical_violation",
      "severity": "high",
      "description": "Taking financial advantage of vulnerable clients",
      "examples": [
        "Excessive fees",
        "Unethical business practices",
        "Pressure to purchase additional services",
        "Lack of transparency about costs"
      ],
      "riskFactors": [
        "Vulnerable clients seeking healing",
        "Power imbalances",
        "Lack of regulation",
        "Absence of price transparency"
      ],
      "prevention": [
        "Clear fee structures",
        "Informed financial consent",
        "Regulatory oversight",
        "Consumer protection laws"
      ],
      "citations": ["evans_holcomb_2025"]
    },
    {
      "id": "boundary_emotional_001",
      "name": "Emotional Manipulation/Abuse",
      "category": "ethical_violation",
      "severity": "high",
      "description": "Using power imbalance to manipulate or emotionally abuse clients",
      "manifestations": [
        "Gaslighting",
        "Shaming",
        "Invalidation of experience",
        "Cult-like dynamics",
        "Isolation from support systems"
      ],
      "riskFactors": [
        "Amplified transference",
        "Heightened emotional state",
        "Suggestibility",
        "Dependency development"
      ],
      "citations": ["muthukumaraswamy_2022"]
    },
    {
      "id": "boundary_epistemic_001",
      "name": "Epistemic Harm/Belief Imposition",
      "category": "ethical_violation",
      "severity": "moderate_to_high",
      "description": "Imposing beliefs or interpretations onto participants",
      "mechanisms": [
        "Interpreting experiences for client",
        "Marginalizing client's perspective",
        "Over-emphasizing specific outcomes (e.g., mystical experiences)",
        "Pressure to adopt facilitator's worldview"
      ],
      "consequences": [
        "False insights becoming solidified beliefs",
        "Undermined autonomy",
        "Psychological distress",
        "Spiritual crisis"
      ],
      "prevention": [
        "Non-directive support",
        "Respecting client's interpretive framework",
        "Not imposing meaning",
        "Cultural humility"
      ],
      "citations": ["zeller_nd", "cheung_nd", "palitsky_nd"]
    }
  ],

  "preparationPractices": [
    {
      "id": "prep_screening_001",
      "name": "Comprehensive Screening",
      "category": "assessment",
      "timing": "pre_session",
      "components": [
        {
          "area": "psychiatric_history",
          "tools": ["Clinical interview", "Structured diagnostic interviews"],
          "focus": [
            "Personal history of mental illness",
            "Family history of psychosis/bipolar",
            "Current symptoms",
            "Treatment history"
          ]
        },
        {
          "area": "medical_history",
          "tools": ["Medical history questionnaire", "Physical exam", "ECG if indicated"],
          "focus": [
            "Cardiovascular conditions",
            "Seizure history",
            "Liver/kidney function",
            "Medication review"
          ]
        },
        {
          "area": "substance_use",
          "tools": ["Substance use history", "Toxicology screening"],
          "focus": [
            "Current substance use",
            "History of substance use disorder",
            "Polydrug patterns"
          ]
        },
        {
          "area": "trauma_history",
          "tools": ["Trauma-focused interview", "Validated trauma scales"],
          "focus": [
            "Types of trauma",
            "PTSD symptoms",
            "Current triggers",
            "Coping strategies"
          ]
        }
      ],
      "exclusionCriteria": [
        "Active psychosis",
        "Active mania",
        "Unstable cardiovascular disease",
        "Severe liver/kidney impairment",
        "Pregnancy",
        "High-risk medications (MAOIs for most substances)"
      ],
      "relativeContraindications": [
        "Family history of psychosis",
        "Personality disorders",
        "Trauma history (requires specialized support)",
        "Controlled cardiovascular conditions"
      ],
      "effectiveness": "high",
      "evidenceQuality": "strong",
      "citations": ["garcia-romeu_2018", "palitsky_nd", "rosa_2022"]
    },
    {
      "id": "prep_psychoeducation_001",
      "name": "Psychoeducation",
      "category": "education",
      "timing": "pre_session",
      "content": [
        {
          "topic": "substance_effects",
          "details": [
            "Mechanism of action",
            "Typical subjective effects",
            "Timeline (onset, peak, duration)",
            "Dose-response relationship"
          ]
        },
        {
          "topic": "potential_experiences",
          "details": [
            "Range of possible experiences",
            "Mystical/transcendent experiences",
            "Challenging/difficult experiences",
            "Somatic effects"
          ]
        },
        {
          "topic": "risks",
          "details": [
            "Psychological risks",
            "Physical risks",
            "What to expect if things get difficult",
            "When to seek help"
          ]
        },
        {
          "topic": "harm_reduction",
          "details": [
            "Set and setting importance",
            "Coping strategies",
            "Integration importance",
            "Avoiding dangerous combinations"
          ]
        }
      ],
      "format": ["Verbal discussion", "Written materials", "Videos"],
      "effectiveness": "moderate_to_high",
      "citations": ["garcia-romeu_2018", "rossi_2022"]
    },
    {
      "id": "prep_intention_setting_001",
      "name": "Intention Setting",
      "category": "psychological",
      "timing": "pre_session",
      "description": "Process of defining clear intentions and goals for the experience",
      "benefits": [
        "Provides structure and direction",
        "Enhances meaning-making",
        "Improves outcomes",
        "Facilitates integration"
      ],
      "process": [
        "Reflection on motivations",
        "Identifying personal goals",
        "Articulating intentions clearly",
        "Discussing with facilitator",
        "Refining intentions"
      ],
      "examples": [
        "Healing from trauma",
        "Understanding life purpose",
        "Connecting with spirituality",
        "Addressing specific symptoms",
        "Personal growth"
      ],
      "effectiveness": "moderate_to_high",
      "citations": ["campo_2024", "haijen_2018", "garel_2023"]
    },
    {
      "id": "prep_life_review_001",
      "name": "Life Review",
      "category": "therapeutic",
      "timing": "pre_session",
      "description": "Comprehensive review of participant's life history",
      "components": [
        "Major life events",
        "Significant relationships",
        "Traumas and challenges",
        "Achievements and strengths",
        "Current life situation",
        "Worldview and beliefs"
      ],
      "purposes": [
        "Build rapport",
        "Identify potential triggers",
        "Understand context",
        "Inform integration",
        "Assess readiness"
      ],
      "duration": "Typically 1-3 sessions",
      "citations": ["garcia-romeu_2018"]
    },
    {
      "id": "prep_practice_skills_001",
      "name": "Coping Skills Training",
      "category": "skills",
      "timing": "pre_session",
      "skills": [
        {
          "skill": "breathing_techniques",
          "description": "Deep breathing exercises for anxiety management",
          "practice": "Taught and practiced in preparation sessions"
        },
        {
          "skill": "grounding_techniques",
          "description": "Methods to stay connected to present moment",
          "examples": ["5-4-3-2-1 sensory exercise", "Body scanning"]
        },
        {
          "skill": "surrender_acceptance",
          "description": "Letting go and accepting the experience",
          "importance": "Strong predictor of positive outcomes"
        },
        {
          "skill": "mindfulness",
          "description": "Non-judgmental awareness",
          "benefit": "Helps navigate difficult moments"
        }
      ],
      "effectiveness": "moderate_to_high",
      "citations": ["robinson_2024", "kirlic_2025"]
    }
  ],

  "integrationPractices": [
    {
      "id": "int_therapy_001",
      "name": "Integration Therapy Sessions",
      "category": "professional_support",
      "timing": "post_session",
      "structure": {
        "initial": {
          "timing": "1-2 days post-session",
          "purpose": "Process immediate experience",
          "duration": "60-90 minutes"
        },
        "ongoing": {
          "frequency": "Weekly to bi-weekly",
          "duration": "1-3 months",
          "purpose": "Translate insights into behavior change"
        }
      },
      "modalities": [
        "Individual therapy",
        "Group therapy",
        "Couples therapy (if relevant)",
        "Family therapy (if relevant)"
      ],
      "therapeuticApproaches": [
        "Psychodynamic",
        "Cognitive-behavioral",
        "Acceptance and Commitment Therapy",
        "Mindfulness-based",
        "Somatic",
        "Transpersonal"
      ],
      "effectiveness": "high",
      "evidenceQuality": "strong",
      "citations": ["garcia-romeu_2018", "bathje_2022"]
    },
    {
      "id": "int_contemplative_001",
      "name": "Contemplative Practices",
      "category": "self_practice",
      "timing": "post_session_ongoing",
      "practices": [
        {
          "practice": "meditation",
          "frequency": "Daily recommended",
          "benefits": ["Sustained awareness", "Emotional regulation", "Integration of insights"]
        },
        {
          "practice": "prayer",
          "context": "For spiritually-oriented individuals",
          "benefits": ["Spiritual connection", "Meaning-making"]
        },
        {
          "practice": "mindfulness",
          "frequency": "Daily informal practice",
          "benefits": ["Present-moment awareness", "Reduced reactivity"]
        }
      ],
      "effectiveness": "moderate_to_high",
      "citations": ["bathje_2022", "piercey_2024"]
    },
    {
      "id": "int_creative_001",
      "name": "Creative Expression",
      "category": "self_practice",
      "timing": "post_session_ongoing",
      "modalities": [
        {
          "modality": "journaling",
          "frequency": "Daily recommended initially",
          "benefits": ["Process experience", "Track insights", "Narrative creation"],
          "commonality": "Very common practice"
        },
        {
          "modality": "art",
          "types": ["Drawing", "Painting", "Sculpture"],
          "benefits": ["Non-verbal processing", "Accessing unconscious material"]
        },
        {
          "modality": "music",
          "types": ["Playing", "Composing", "Listening intentionally"],
          "benefits": ["Emotional processing", "Accessing experience"]
        },
        {
          "modality": "writing",
          "types": ["Poetry", "Prose", "Letters"],
          "benefits": ["Meaning-making", "Articulation of ineffable experiences"]
        }
      ],
      "effectiveness": "moderate",
      "citations": ["bathje_2022", "cavarra_2022", "gezon_2024"]
    },
    {
      "id": "int_somatic_001",
      "name": "Somatic Practices",
      "category": "mind_body",
      "timing": "post_session_ongoing",
      "practices": [
        {
          "practice": "yoga",
          "frequency": "Regular practice",
          "benefits": ["Embodiment", "Trauma processing", "Grounding"],
          "evidence": "Particularly important for ayahuasca integration"
        },
        {
          "practice": "breathwork",
          "types": ["Holotropic", "Pranayama", "Box breathing"],
          "benefits": ["Continued access to non-ordinary states", "Emotional release"]
        },
        {
          "practice": "qi_gong",
          "benefits": ["Energy cultivation", "Mind-body integration"]
        },
        {
          "practice": "somatic_psychotherapy",
          "benefits": ["Trauma processing", "Body-based integration"]
        }
      ],
      "effectiveness": "moderate_to_high",
      "specialRelevance": "Especially important for trauma processing and ayahuasca",
      "citations": ["bathje_2022", "cowley-court_2023"]
    },
    {
      "id": "int_nature_001",
      "name": "Nature Connection",
      "category": "environmental",
      "timing": "post_session_ongoing",
      "activities": [
        "Forest bathing",
        "Hiking",
        "Gardening",
        "Simply spending time outdoors"
      ],
      "benefits": [
        "Grounding",
        "Perspective",
        "Connection to larger whole",
        "Stress reduction"
      ],
      "commonality": "Widely reported as beneficial",
      "citations": ["piercey_2024", "robinson_2024"]
    },
    {
      "id": "int_peer_support_001",
      "name": "Peer Support and Integration Circles",
      "category": "community",
      "timing": "post_session_ongoing",
      "formats": [
        {
          "format": "integration_circles",
          "structure": "Regular meetings with facilitation",
          "benefits": [
            "Shared experience",
            "Reduced isolation",
            "Community support",
            "Normalize challenges"
          ]
        },
        {
          "format": "online_forums",
          "benefits": ["Accessible", "Anonymous option", "Ongoing support"]
        },
        {
          "format": "peer_mentoring",
          "structure": "One-on-one with experienced integrator",
          "benefits": ["Personalized support", "Practical guidance"]
        }
      ],
      "risks": [
        "Exposure to misinformation",
        "Cultic dynamics",
        "Lack of clinical oversight"
      ],
      "bestPractices": [
        "Trained facilitators",
        "Clear guidelines",
        "Professional consultation available"
      ],
      "effectiveness": "moderate_to_high",
      "citations": ["cheung_nd", "robinson_2024", "gezon_2024"]
    },
    {
      "id": "int_lifestyle_001",
      "name": "Lifestyle Changes",
      "category": "behavioral",
      "timing": "post_session_ongoing",
      "changes": [
        {
          "area": "diet",
          "commonChanges": ["Healthier eating", "Mindful eating", "Reduced processed foods"],
          "motivations": "Insights about health and body"
        },
        {
          "area": "exercise",
          "commonChanges": ["Increased physical activity", "New exercise routines"],
          "benefits": ["Physical health", "Mental health", "Embodiment"]
        },
        {
          "area": "relationships",
          "commonChanges": ["Boundary setting", "Communication improvement", "Letting go of toxic relationships"],
          "motivations": "Insights about relational patterns"
        },
        {
          "area": "work_career",
          "commonChanges": ["Career changes", "Work-life balance adjustment", "Purpose-driven work"],
          "motivations": "Insights about life purpose and values"
        }
      ],
      "citations": ["piercey_2024", "bathje_2022"]
    }
  ],

  "groupDynamicsFactors": [
    {
      "id": "group_preexisting_tensions_001",
      "name": "Pre-existing Relationship Tensions",
      "category": "interpersonal",
      "description": "Using psychedelics with people with whom there are unresolved conflicts",
      "prevalence": {
        "value": 33,
        "unit": "percent",
        "context": "Of those with negative experiences took psychedelics with someone they had relationship issues with",
        "citation": "bremler_2023"
      },
      "riskLevel": "moderate_to_high",
      "specificRisks": [
        "Amplification of conflicts",
        "Challenging experiences",
        "Relationship damage"
      ],
      "nuance": {
        "intentional": "Some people intentionally use psychedelics to work through relationship issues",
        "riskOfIntentional": "This can be problematic",
        "citation": "bremler_2023"
      },
      "recommendations": [
        "Avoid using with people you have active conflicts with",
        "If working on relationships, do so with professional facilitation",
        "Ensure supportive, not antagonistic, setting"
      ]
    },
    {
      "id": "group_composition_001",
      "name": "Group Composition and Power Dynamics",
      "category": "structural",
      "description": "The makeup of the group and power relationships within it",
      "components": [
        {
          "aspect": "size",
          "considerations": ["Larger groups may be harder to manage", "Individual attention availability"]
        },
        {
          "aspect": "familiarity",
          "considerations": ["Strangers vs. known participants", "Trust levels"]
        },
        {
          "aspect": "hierarchies",
          "considerations": ["Teacher-student dynamics", "Leader-follower dynamics", "Guru models"],
          "risks": ["Exploitation", "Undue influence", "Boundary violations"]
        },
        {
          "aspect": "diversity",
          "considerations": ["Cultural backgrounds", "Experience levels", "Intentions"]
        }
      ],
      "riskFactors": [
        "Unresolved conflicts",
        "Power imbalances",
        "Lack of trust",
        "Divergent intentions"
      ],
      "citations": ["palitsky_nd", "argyri_2024", "spriggs_2023"]
    },
    {
      "id": "group_suggestibility_001",
      "name": "Collective Suggestibility and Belief Shaping",
      "category": "psychological",
      "description": "Heightened suggestibility in group settings during psychedelic states",
      "mechanism": "Psychedelics increase suggestibility, amplified in group contexts",
      "risks": [
        "Adoption of harmful beliefs",
        "Cult-like dynamics",
        "Unwarranted beliefs",
        "Loss of individual perspective"
      ],
      "benefits": [
        "Positive belief adoption possible",
        "Shared mystical experience",
        "Group cohesion"
      ],
      "bidirectional": "Can lead to healthy or unhealthy outcomes",
      "citations": ["cheung_nd", "robinson_2024", "kruger_2024"]
    },
    {
      "id": "group_contagion_001",
      "name": "Emotional Contagion",
      "category": "psychological",
      "description": "Spread of emotional states within group",
      "mechanism": "Intense emotions during psychedelic states can spread between participants",
      "specificRisks": [
        "Anxiety spreading",
        "Panic spreading",
        "Paranoia spreading",
        "Cascade of challenging experiences"
      ],
      "prevention": [
        "Adequate facilitator-to-participant ratios",
        "Individual spaces available",
        "Trained facilitators who can isolate distressed participants",
        "Pre-session group agreements"
      ],
      "citations": ["bremler_2023", "breeksema_2022"]
    },
    {
      "id": "group_cohesion_001",
      "name": "Group Cohesion Effects",
      "category": "social",
      "description": "Strong bonding that can occur through shared psychedelic experiences",
      "positiveEffects": [
        "Sense of unity",
        "Reduced isolation",
        "Mutual support",
        "Shared understanding"
      ],
      "risks": [
        "Cult-like dynamics",
        "In-group/out-group thinking",
        "Pressure to conform",
        "Difficulty leaving group"
      ],
      "citations": ["cheung_nd", "evans_holcomb_2025"]
    }
  ],

  "culturalSpiritualFactors": [
    {
      "id": "cultural_context_001",
      "name": "Cultural Context and Understanding",
      "category": "cultural",
      "description": "Alignment or misalignment between psychedelic experience and cultural framework",
      "importance": "high",
      "risks": [
        {
          "risk": "cultural_misinterpretation",
          "description": "Interpreting experiences through inappropriate cultural lens",
          "consequences": ["Confusion", "Distress", "Inappropriate integration"]
        },
        {
          "risk": "lack_of_cultural_context",
          "description": "Experiencing effects without cultural framework to make sense of them",
          "consequences": ["Disorientation", "Inability to integrate"]
        },
        {
          "risk": "cultural_appropriation",
          "description": "Western adoption of Indigenous practices without respect or understanding",
          "consequences": ["Harm to Indigenous communities", "Trivialization of sacred practices", "Loss of traditional knowledge"]
        }
      ],
      "considerations": [
        "Western medicalization of Indigenous practices",
        "Respect for traditional knowledge",
        "Benefit-sharing with source communities",
        "Avoiding exploitation"
      ],
      "specificContexts": [
        {
          "context": "Indigenous ceremonies",
          "considerations": ["Cultural protocols", "Language", "Worldview", "Community practices"]
        },
        {
          "context": "Western therapeutic",
          "considerations": ["Scientific framework", "Individualistic orientation", "Clinical protocols"]
        },
        {
          "context": "Religious/spiritual groups",
          "considerations": ["Specific belief systems", "Ritual elements", "Community integration"]
        }
      ],
      "citations": ["argyri_2024", "hartogsohn_2024", "walther_2024", "bathje_2022", "barber_2023"]
    },
    {
      "id": "cultural_competence_001",
      "name": "Culturally Competent Care",
      "category": "therapeutic",
      "description": "Providing care that respects and responds to cultural backgrounds",
      "importance": "critical",
      "lackOfImpact": {
        "description": "Lack of culturally competent care can lead to poor outcomes",
        "specificPopulations": ["BIPOC", "Immigrant communities", "Indigenous peoples"]
      },
      "components": [
        "Understanding cultural influences on experience",
        "Respecting diverse belief systems",
        "Avoiding cultural impositions",
        "Tailoring interventions",
        "Using culturally appropriate assessment tools"
      ],
      "diversityInResearch": {
        "problem": "82.3% of participants 1993-2017 were non-Hispanic White",
        "consequence": "Limited generalizability of findings",
        "citation": "michaels_2018"
      },
      "recommendations": [
        "Diversify research participation",
        "Train practitioners in cultural competence",
        "Develop culturally-adapted interventions",
        "Include diverse perspectives in treatment development"
      ],
      "citations": ["evans_2023", "haft_2025", "rajwani_2022"]
    },
    {
      "id": "spiritual_struggles_001",
      "name": "Spiritual Struggles and Crises",
      "category": "spiritual",
      "description": "Distressing spiritual or existential experiences",
      "manifestations": [
        "Ontological shock",
        "Existential crises",
        "Spiritual emergency",
        "Loss of meaning",
        "Conflict with existing beliefs"
      ],
      "prevalence": "Common but often underreported",
      "riskFactors": [
        "Strong pre-existing religious beliefs",
        "Rigid belief systems",
        "Lack of spiritual framework",
        "Dismissal of spiritual experiences by facilitators"
      ],
      "consequences": [
        "Confusion",
        "Disorientation",
        "Psychological distress",
        "Difficulty integrating",
        "Potential for growth if properly supported"
      ],
      "support": [
        "Spiritually-responsive care",
        "Avoiding spiritual imposition",
        "Respecting individual spiritual frameworks",
        "Specialized integration support"
      ],
      "citations": ["palitsky_2024", "robinson_2024", "breeksema_2022"]
    }
  ],

  "legalSocioeconomicFactors": [
    {
      "id": "legal_prohibition_001",
      "name": "Prohibition and Illegal Status",
      "category": "legal",
      "description": "Harms arising from criminalization of psychedelics",
      "impacts": [
        {
          "impact": "lack_of_quality_control",
          "severity": "high",
          "description": "Absence of regulation leads to variable purity and unknown adulterants",
          "consequences": ["Unpredictable effects", "Toxicity", "Overdose risk"]
        },
        {
          "impact": "unsafe_acquisition",
          "severity": "moderate_to_high",
          "description": "Exposure to criminal markets",
          "consequences": ["Violence", "Theft", "Intimidation", "Contact with criminal organizations"]
        },
        {
          "impact": "reluctance_to_seek_help",
          "severity": "high",
          "description": "Fear of legal repercussions prevents help-seeking",
          "consequences": ["Adverse events not treated", "Poor outcomes", "Deaths"]
        },
        {
          "impact": "research_barriers",
          "severity": "high",
          "description": "Schedule I classification limits research",
          "consequences": ["Limited safety data", "Slow development of protocols", "Insufficient evidence"]
        },
        {
          "impact": "disproportionate_enforcement",
          "severity": "high",
          "description": "Racialized drug policies lead to disproportionate arrests",
          "consequences": ["Criminalization of minorities", "Police violence risk", "Sense of unsafety"],
          "citations": ["rajwani_2022", "jones_2022"]
        }
      ],
      "citations": ["davis_nd", "rajwani_2022", "barber_2023", "kopra_2025"]
    },
    {
      "id": "socioeconomic_access_001",
      "name": "Socioeconomic Barriers to Access",
      "category": "socioeconomic",
      "description": "Financial and resource barriers limiting access to safe use",
      "barriers": [
        {
          "barrier": "cost_of_therapy",
          "description": "Psychedelic therapy can cost $25,000+ per course",
          "impact": "Only wealthy can access",
          "citation": "barber_2024"
        },
        {
          "barrier": "lack_of_insurance_coverage",
          "description": "Most psychedelic therapies not covered by insurance",
          "impact": "Out-of-pocket costs prohibitive"
        },
        {
          "barrier": "geographic_disparities",
          "description": "Services concentrated in urban, wealthy areas",
          "impact": "Rural and underserved areas lack access"
        },
        {
          "barrier": "transportation",
          "description": "Multiple sessions require reliable transportation",
          "impact": "Difficult for those without vehicles or access to transit"
        },
        {
          "barrier": "time_off_work",
          "description": "Sessions and integration require time away from employment",
          "impact": "Those with inflexible jobs or hourly wages cannot participate"
        }
      ],
      "consequences": [
        "Wealthy get therapeutic access; poor relegated to unregulated market",
        "Higher rates of unsafe use in lower SES populations",
        "Health disparities amplified"
      ],
      "citations": ["barber_2024", "wilson-poe_2024", "rosa_2022"]
    },
    {
      "id": "socioeconomic_unsafe_use_001",
      "name": "Economic Stress and Unsafe Use Patterns",
      "category": "socioeconomic",
      "description": "How poverty and economic stress increase risks",
      "mechanisms": [
        {
          "mechanism": "self_medication",
          "description": "Using psychedelics to cope with untreated mental health issues",
          "reason": "Lack of affordable mental health care"
        },
        {
          "mechanism": "unsafe_contexts",
          "description": "Use in uncontrolled environments without support",
          "reason": "Cannot afford therapeutic settings"
        },
        {
          "mechanism": "polydrug_use",
          "description": "Higher rates of mixing substances",
          "context": "Found in lower SES populations",
          "citation": "kopra_2025"
        },
        {
          "mechanism": "mental_health_burden",
          "description": "Poverty, unstable housing, income inequality linked to mental health disorders",
          "consequence": "Increased vulnerability to adverse reactions",
          "citation": "bremler_2023"
        }
      ],
      "overdoseData": {
        "finding": "Overdose death rates highest in counties with highest income inequality",
        "population": "Black persons particularly affected",
        "rate": "46.5 per 100,000 in high inequality counties",
        "citation": "jegede_2024"
      }
    },
    {
      "id": "socioeconomic_healthcare_access_001",
      "name": "Limited Healthcare Access",
      "category": "socioeconomic",
      "description": "Inability to access medical and mental health services for adverse events",
      "statistics": {
        "needingProfessionalHelp": {
          "value": 2.6,
          "unit": "percent",
          "context": "Of non-clinical psychedelic users require medical/psychiatric assistance",
          "citation": "palitsky_nd"
        }
      },
      "impacts": [
        "Adverse events untreated or undertreated",
        "Long-term negative effects more likely",
        "Higher rates of poor outcomes"
      ],
      "populations": "Particularly affects uninsured, underinsured, rural populations"
    }
  ],

  "contaminationQualityFactors": [
    {
      "id": "contam_adulterants_001",
      "name": "Adulteration with Novel Psychoactive Substances",
      "category": "contamination",
      "severity": "high",
      "description": "Presence of substances other than the purported psychedelic",
      "commonAdulterants": [
        {
          "adulterant": "NBOMe compounds",
          "substances_sold_as": ["LSD", "MDMA"],
          "risks": [
            "Higher toxicity than advertised substance",
            "Unpredictable effects",
            "Prolonged effects",
            "Severe adverse reactions",
            "Fatalities documented"
          ],
          "citations": ["hirschfeld_2021", "malcolm_2022"]
        },
        {
          "adulterant": "DOx family (dimethoxyamphetamines)",
          "substances_sold_as": ["LSD", "MDMA", "psilocybin powder"],
          "risks": ["Severe side effects", "Prolonged duration", "Hospitalizations"]
        },
        {
          "adulterant": "Atropine-like substances",
          "substances_sold_as": ["LSD"],
          "risks": ["Psychotic symptoms", "Anticholinergic toxicity"],
          "citation": "sabe_2024"
        },
        {
          "adulterant": "Fentanyl and opioids",
          "substances_sold_as": ["MDMA"],
          "risks": ["Overdose", "Death"],
          "prevalence": "Significant concern",
          "citation": "rajwani_2022"
        },
        {
          "adulterant": "PMMA (paramethoxymethamphetamine)",
          "substances_sold_as": ["MDMA", "ecstasy"],
          "risks": ["More toxic than MDMA", "Fatalities documented"],
          "citation": "haden_2016"
        }
      ],
      "prevalenceExamples": [
        {
          "substance": "MDMA pills",
          "purity": "63% contained MDMA or analog; 29% contained other identifiable drugs",
          "citation": "banta-green_2005"
        }
      ],
      "harmReduction": [
        "Substance testing with reagent kits",
        "Drug checking services",
        "Purchasing from trusted sources",
        "Starting with test dose"
      ]
    },
    {
      "id": "contam_purity_variability_001",
      "name": "Purity and Potency Variability",
      "category": "quality",
      "severity": "high",
      "description": "Inconsistent concentration of active substance",
      "substanceExamples": [
        {
          "substance": "psilocybin mushrooms",
          "variability": "Significant between species, growing conditions, storage",
          "consequence": "Difficult to achieve consistent dosing",
          "risk": "Accidental overdose or under-dosing",
          "citations": ["johnson_2018", "kopra_2022"]
        },
        {
          "substance": "LSD blotters",
          "variability": "Hot spots and cold spots within same batch",
          "consequence": "Unpredictable dosing",
          "risk": "Accidental overdose",
          "citations": ["miller_2024"]
        },
        {
          "substance": "MDMA tablets",
          "variability": "Increasing average content (2-3x typical dose common)",
          "consequence": "Higher risk of toxicity",
          "citations": ["edwards_2023"]
        },
        {
          "substance": "ibogaine extract",
          "variability": "Range from 8.2% to 32.9% purity in extracts; 61.5% to 73.4% in hydrochloride",
          "consequence": "Difficult to determine safe dosing",
          "citations": ["rocha_2023"]
        }
      ],
      "mechanisms": [
        "Natural variability in plant sources",
        "Inconsistent extraction/synthesis processes",
        "Degradation during storage",
        "Uneven distribution in preparations"
      ],
      "harmReduction": [
        "Use standardized pharmaceutical-grade substances when possible",
        "Test substances",
        "Start with lower doses",
        "Volumetric dosing for consistency"
      ]
    },
    {
      "id": "contam_storage_degradation_001",
      "name": "Storage and Degradation",
      "category": "quality",
      "severity": "moderate",
      "description": "Loss of potency over time due to improper storage",
      "substanceExamples": [
        {
          "substance": "psilocybin",
          "degradation": "Up to 50% loss within months",
          "factors": ["Light", "Heat", "Moisture", "Oxygen"],
          "comparison": "Fresh mushrooms degrade faster than dried",
          "citations": ["cavanna_2022", "gotvaldova_2020"]
        }
      ],
      "consequences": [
        "Unpredictable potency",
        "Weaker than expected effects",
        "Dosing difficulties"
      ],
      "prevention": [
        "Proper storage (cool, dark, dry, airtight)",
        "Use within recommended timeframe",
        "Be aware of age of substances"
      ]
    },
    {
      "id": "contam_misidentification_001",
      "name": "Botanical Misidentification",
      "category": "sourcing",
      "severity": "high",
      "description": "Incorrect identification of psychedelic plants/mushrooms",
      "risks": [
        "Consumption of toxic species",
        "Poisoning",
        "Death"
      ],
      "substanceExamples": [
        {
          "substance": "psilocybin mushrooms",
          "risk": "Confusion with toxic mushroom species",
          "consequence": "Severe illness or death from toxic mushrooms",
          "citation": "kopra_2022"
        },
        {
          "substance": "ayahuasca plants",
          "risk": "Using wrong plant species in brew",
          "consequence": "Toxic compounds or ineffective brew",
          "citation": "white_2024"
        }
      ],
      "prevention": [
        "Expert botanical identification",
        "Avoid foraging without expertise",
        "Purchase from reputable sources",
        "Use standardized preparations when available"
      ]
    }
  ],

  "emergencyResponseProtocols": [
    {
      "id": "emergency_nonpharm_001",
      "name": "Non-Pharmacological Interventions",
      "category": "crisis_management",
      "priority": "first_line",
      "interventions": [
        {
          "intervention": "continuous_monitoring",
          "description": "Maintain observation and regular verbal contact",
          "frequency": "Continuous throughout session",
          "citations": ["carbonaro_2016"]
        },
        {
          "intervention": "verbal_reassurance",
          "description": "Remind that experience is temporary, drug-related, and they are safe",
          "effectiveness": "Sufficient for most distress",
          "technique": "Calm, empathetic, non-judgmental",
          "citations": ["garcia-romeu_2018", "johnson_2008"]
        },
        {
          "intervention": "calm_presence",
          "description": "Facilitator maintains calm demeanor",
          "rationale": "Reduces participant anxiety through modeling",
          "citations": ["psychedelic_drug_crises_2024"]
        },
        {
          "intervention": "breathing_guidance",
          "description": "Guide slow, deep breathing",
          "technique": "Simple, clear instructions",
          "benefits": ["Anxiety reduction", "Grounding"],
          "citations": ["psychedelic_drug_crises_2024", "ching_2024"]
        },
        {
          "intervention": "grounding_techniques",
          "description": "Help participant focus on present moment and physical sensations",
          "examples": ["Focus on breath", "Feel feet on ground", "Notice sounds"],
          "citations": ["ching_2024", "mcalpine_2024"]
        },
        {
          "intervention": "environmental_adjustment",
          "description": "Modify setting to reduce distress",
          "actions": [
            "Move to quiet area",
            "Dim lights",
            "Reduce noise",
            "Adjust temperature",
            "Remove overstimulating elements"
          ],
          "citations": ["johnson_2008", "barnett_2021", "psychedelic_drug_crises_2024"]
        },
        {
          "intervention": "physical_contact",
          "description": "Gentle, reassuring touch if appropriate",
          "requirements": ["Participant consent", "Cultural appropriateness"],
          "examples": ["Hand on shoulder", "Hand holding if welcomed"],
          "citation": "psychedelic_drug_crises_2024"
        },
        {
          "intervention": "avoid_arguing",
          "description": "Do not challenge altered perceptions",
          "rationale": "Can escalate distress",
          "citation": "psychedelic_drug_crises_2024"
        }
      ],
      "effectiveness": "High - manages most cases of distress",
      "citations": ["johnson_2008", "davis_2022"]
    },
    {
      "id": "emergency_pharm_001",
      "name": "Pharmacological Interventions",
      "category": "crisis_management",
      "priority": "second_line",
      "whenToUse": "If non-pharmacological approaches insufficient",
      "medications": [
        {
          "medication": "benzodiazepines",
          "specific": "diazepam",
          "status": "preferred_first_line_pharmacological",
          "dosing": {
            "typical": {"value": 10, "unit": "mg", "route": "oral"},
            "emergency": {"min": 15, "max": 30, "unit": "mg", "context": "May be necessary"}
          },
          "mechanism": "Anxiolytic, reduces agitation",
          "advantages": ["Rapid onset", "Shorter duration", "Effective for anxiety"],
          "availability": "Should be readily available",
          "citations": ["johnson_2008", "barnett_2021"]
        },
        {
          "medication": "antipsychotics",
          "examples": ["risperidone", "olanzapine"],
          "status": "last_resort",
          "whenToUse": "Severe psychosis unresponsive to benzodiazepines",
          "cautions": [
            "Use with caution",
            "May cause unpleasant/intense effects",
            "Haloperidol may exacerbate psychosis-like symptoms - avoid"
          ],
          "citations": ["johnson_2008", "barnett_2021", "hughes_2016"]
        },
        {
          "medication": "ketanserin",
          "type": "5-HT2A_antagonist",
          "status": "experimental",
          "evidence": "Shows promise in attenuating psilocybin effects",
          "availability": "Not approved in USA",
          "citation": "johnson_2008"
        }
      ],
      "administration": "By trained medical personnel only",
      "documentation": "All interventions must be documented"
    },
    {
      "id": "emergency_medical_001",
      "name": "Emergency Medical Services",
      "category": "crisis_management",
      "priority": "escalation",
      "whenToCall": [
        "Condition does not improve with interventions",
        "Severe physiological symptoms (chest pain, seizure, hyperthermia)",
        "Suspected overdose",
        "Suicidal ideation or behavior",
        "Violent or dangerous behavior",
        "Medical emergency"
      ],
      "preparedness": [
        "Clear protocol for contacting EMS",
        "Emergency numbers readily available",
        "Address and location information prepared",
        "Medical history available if possible"
      ],
      "prevention": "Proper screening and preparation reduce need for EMS",
      "prevalenceData": {
        "firstTimeLSD": {
          "value": 0.5,
          "unit": "percent",
          "context": "Seeking serious adverse events requiring EMT",
          "citation": "baxter_2024"
        },
        "general2020": {
          "lsd": 1,
          "mdma": 1,
          "ketamine": 0.6,
          "psilocybin": 0.6,
          "unit": "percent",
          "citation": "canady_2023"
        }
      }
    },
    {
      "id": "emergency_helpline_001",
      "name": "Psychedelic Crisis Helplines",
      "category": "peer_support",
      "description": "Professional peer support via telephone for acute crises",
      "examples": [
        {
          "organization": "Fireside Project",
          "availability": "Telephone helpline",
          "effectiveness": {
            "deescalation": {
              "value": 65.9,
              "unit": "percent",
              "description": "Successfully de-escalated from psychological distress"
            },
            "preventedHarm": {
              "possibleHarm": 29.3,
              "might911": 12.5,
              "mightER": 10.8,
              "unit": "percent"
            }
          },
          "citations": ["pleet_2023", "canady_2023"]
        },
        {
          "organization": "Zendo Project",
          "setting": "On-site at festivals/events",
          "model": "Peer support in safe space",
          "effectiveness": "Reduces need for medical/emergency support",
          "citations": ["ruane_2015", "cheung_nd"]
        }
      ],
      "impact": "Can prevent escalation and reduce burden on emergency services"
    }
  ],

  "assessmentTools": [
    {
      "id": "tool_spsi_001",
      "name": "Swiss Psychedelic Side Effects Inventory (SPSI)",
      "purpose": "Systematic assessment of adverse effects",
      "type": "psychedelic_specific",
      "domains": [
        "Psychological symptoms",
        "Physical symptoms",
        "Perceptual disturbances",
        "Social/interpersonal effects"
      ],
      "advantages": [
        "Standardized",
        "Comprehensive",
        "Improves data quality"
      ],
      "citation": "calder_2024"
    },
    {
      "id": "tool_dysfunctional_attitude_001",
      "name": "Dysfunctional Attitude Scale",
      "purpose": "Measure dysfunctional beliefs and attitudes",
      "relevance": "Predicts challenging experiences",
      "note": "Those with higher scores may have more difficult experiences",
      "citation": "anderson_2019"
    }
  ],

  "doseResponseCurves": [
    {
      "substanceId": "psilocybin_001",
      "adverseEventId": "ae_anxiety_acute_001",
      "relationship": "positive_correlation",
      "dataPoints": [
        {"dose": 50, "unit": "mcg", "prevalence": 9, "unit_prevalence": "percent", "context": "bad drug effects", "citation": "holze_2022"},
        {"dose": 100, "unit": "mcg", "prevalence": 27, "unit_prevalence": "percent", "context": "bad drug effects", "citation": "holze_2022"},
        {"dose": 200, "unit": "mcg", "prevalence": 31, "unit_prevalence": "percent", "context": "bad drug effects", "citation": "holze_2022"}
      ],
      "interpretation": "Higher doses associated with increased prevalence of adverse effects",
      "evidenceQuality": "strong"
    },
    {
      "substanceId": "psilocybin_001",
      "outcome": "mystical_experience",
      "relationship": "positive_correlation",
      "dataPoints": [
        {"dose": 0, "unit": "mg/kg", "prevalence": 0, "unit_prevalence": "percent"},
        {"dose": 0.07, "unit": "mg/kg", "prevalence": 5.6, "unit_prevalence": "percent"},
        {"dose": 0.14, "unit": "mg/kg", "prevalence": 11.1, "unit_prevalence": "percent"},
        {"dose": 0.29, "unit": "mg/kg", "prevalence": 44.4, "unit_prevalence": "percent"},
        {"dose": 0.43, "unit": "mg/kg", "prevalence": 55.6, "unit_prevalence": "percent"}
      ],
      "interpretation": "Clear dose-response relationship for mystical experiences",
      "citation": "bender_2022"
    }
  ],

  "complexInteractions": [
    {
      "id": "interact_complex_001",
      "factors": [
        {"type": "substance", "id": "psilocybin_001"},
        {"type": "medical_condition", "id": "cond_bipolar_001"},
        {"type": "setting", "id": "setting_recreational_001"},
        {"type": "risk_factor", "id": "rf_unprepared_001"}
      ],
      "riskMultiplier": "high",
      "specificOutcome": "Increased risk of manic episode in uncontrolled setting",
      "evidenceQuality": "moderate",
      "mitigatingFactors": [
        "Controlled therapeutic setting reduces risk",
        "Proper screening and preparation essential",
        "Monitoring during and after session"
      ],
      "citations": ["honk_2024", "bremler_2023"]
    },
    {
      "id": "interact_complex_002",
      "factors": [
        {"type": "substance", "id": "mdma_001"},
        {"type": "risk_factor", "id": "rf_gender_sex_001", "specific": "female"},
        {"type": "risk_factor", "id": "rf_low_bmi_001"},
        {"type": "setting", "id": "setting_recreational_001", "specific": "hot_environment"}
      ],
      "riskMultiplier": "very_high",
      "specificOutcome": "Severe hyponatremia risk",
      "mechanism": [
        "Higher plasma MDMA in females with low BMI",
        "Hot environment increases fluid intake",
        "Dancing increases water loss and hypotonic replacement"
      ],
      "prevention": [
        "Education about appropriate hydration",
        "Avoid hot environments",
        "Fluid restriction strategies",
        "Increased monitoring"
      ],
      "evidenceQuality": "strong",
      "citations": ["atila_2024", "papaseit_2018"]
    },
    {
      "id": "interact_complex_003",
      "factors": [
        {"type": "substance", "id": "5meo_dmt_001"},
        {"type": "drug_interaction", "id": "interaction_maoi_001"},
        {"type": "route", "id": "roa_oral_001"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Potentially fatal serotonin syndrome",
      "mechanism": "MAOIs increase 5-MeO-DMT exposure up to sixfold",
      "contraindicationType": "absolute",
      "deathsReported": true,
      "evidenceQuality": "strong",
      "citations": ["malcolm_2022"]
    }
  ],

  "metadata": {
    "documentSource": "Psychedelic Safety Institute Literature Review",
    "totalCitations": 400,
    "primaryResearchTypes": [
      "clinical_trials",
      "observational_studies",
      "surveys",
      "case_reports",
      "literature_reviews"
    ],
    "geographicScope": "Global with emphasis on North America and Europe",
    "lastLiteratureSearch": "2024",
    "qualityAssessment": "Comprehensive but varies by substance and outcome",
    "knownLimitations": [
      "Underreporting of adverse events likely",
      "Limited diversity in research populations",
      "Few long-term follow-up studies",
      "Variable methodology across studies",
      "Small sample sizes for many substances"
    ]
  }
}